[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363498-105":59,"doc-detail-363498-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tropion-urothelial03-a-phase-iiiii-study-of-datopotamab-deruxtecan-dato-dxd-for-locally-advanced-or-metastatic-urothelial-carcinoma","TROPION-Urothelial03 - a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma","","Enfortumab vedotin plus pembrolizumab is the first-line standard for locally advanced or metastatic urothelial carcinoma, but treatment options after progression are limited. Datopotamab deruxtecan, a trophoblast cell surface antigen 2–directed antibody–drug conjugate, has shown durable activity and manageable safety in this setting. TROPION-Urothelial03 is a global phase II/III trial comparing Dato-DXd plus platinum chemotherapy versus gemcitabine plus platinum in patients progressing on or after EV plus pembrolizumab. Part A evaluates dosing with ORR; Part B assesses PFS and overall survival with additional ORR and response duration.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tropion-urothelial03-a-phase-iiiii-study-of-datopotamab-deruxtecan-dato-dxd-for-locally-advanced-or-metastatic-urothelial-carcinoma/363498/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tropion-urothelial03-a-phase-iiiii-study-of-datopotamab-deruxtecan-dato-dxd-for-locally-advanced-or-metastatic-urothelial-carcinoma/363498.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical situation does TROPION-Urothelial03 address?","Question",{"text":113,"@type":114},"Patients with locally advanced or metastatic urothelial carcinoma whose disease progresses on or after enfortumab vedotin plus pembrolizumab.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the trial compare treatments in Parts A and B?",{"text":118,"@type":114},"Part A (phase II) randomizes ~60 patients 1:1 to Dato-DXd 4 mg/kg or 6 mg/kg with platinum chemotherapy to determine optimal dosing. Part B (phase III) randomizes ~570 patients 1:1 to Dato-DXd at the recommended dose plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the primary endpoints for each part of the study?",{"text":122,"@type":114},"Part A primary endpoint is objective response rate (ORR). Part B dual primary endpoints are progression-free survival (PFS) by blinded independent central review and overall survival.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363498,1790196259,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 12, 1387–1396  \n[https://doi.org/10.1080/14796694.2026.2663956](https://doi.org/10.1080/14796694.2026.2663956)  \nCLINICAL TRIAL PROTOCOL  \nTROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma  \nMatthew D. Galsky a, Alexandra Drakaki b, Arnab Basu c, Bradley McGregor d, Jens Bedke e, Yohann Loriot f, Eiji Kikuchi g, Jun Guoh, Benjamin Garmezy i, Srikala S. Sridhar j, Parminder Singhk, Vadim S. Koshkin l, Mark Flemingm, Gunnar Klaussn, Daisy Lino, Chelsea Liup, Andrea B. Apolo q and Thomas Powles r  \naDepartment of Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; bDepartment of Medical Oncology, UCLA Health, Los Angeles, CA, USA; cDepartment of Oncology, Mayo Clinic, Jacksonville, FL, USA; dDepartment of Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; e Department of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Germany; fDepartment of Oncology, Gustave Roussy Cancer Institute, Paris, France; gDepartment of Urology, St. Marianna University School of Medicine, Kawasaki, Japan; hDepartment of Oncology, Peking University Cancer Hospital and Research Institute, Beijing, China; iDepartment of Genitourinary Cancer Research, Sarah Cannon Research Institute, Nashville, TN, USA; jDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; kDepartment of Genitourinary Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA; lDivision of Hematology/Oncology, Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer, San Francisco, CA, USA; m Department of Medical Oncology, Virginia Oncology Associates, Brock Cancer Center, Norfolk, VA, USA; n Department of Global Oncology Research & Development, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; o Department of Clinical Science Therapeutic Area Oncology, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; pDepartment of Biostatistics & Data Management, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; qDepartment of Oncology, National Cancer Institute, Bethesda, MD, USA; rCentre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK  \nABSTRACT  \nEnfortumab vedotin (EV) plus pembrolizumab is the first-line standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). However, randomized data to guide treatment after progression on EV plus pembrolizumab are limited. Datopotamab deruxtecan (Dato-DXd), a trophoblast cell surface antigen 2–directed antibody–drug conjugate, has demonstrated durable efficacy and a manageable safety profile in patients with la/mUC. TROPION-Urothelial03 is a global, multicenter, randomized, openlabel, phase II/III trial comparing the efficacy and safety of Dato-DXd plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy in patients with la/mUC and disease progression on or after EV plus pembrolizumab. In Part A (phase II), ~60 patients will be randomized 1:1 to Dato-DXd 4 or 6 mg/kg plus platinum chemotherapy to determine optimal dosing. In Part B (phase III), ~570 patients will be randomized 1:1 to receive Dato-DXd at the recommended phase III dose plus platinum chemotherapy or gemcitabine plus platinum chemotherapy. The primary endpoint of Part A is objective response rate (ORR); the dual primary endpoints of Part B are progression-free survival (PFS) by blinded independent central review (BICR) and overall survival. Secondary endpoints include duration of response by investigator (Part A), and PFS by investigator and ORR by BICR and investigator (Part B).  \nClinical trial [registration:](registration: www.clinicaltrials.gov)[ www.clinicaltrials.gov](registration: www.clinicaltrials.gov) identifier is NCT07129993.  \nPLAIN LANGUAGE SUMMARY  \nPatients diagnosed with a type of bladder cancer called urothelial carcinoma (UC)","cbCaiuzEnnCIcESf","https://ap.wps.com/l/cbCaiuzEnnCIcESf","pdf",3099254,"English","# Introduction\n## Background and rationale\n## Trial overview and design\n## Endpoints and assessments","[{\"question\":\"What clinical situation does TROPION-Urothelial03 address?\",\"answer\":\"Patients with locally advanced or metastatic urothelial carcinoma whose disease progresses on or after enfortumab vedotin plus pembrolizumab.\"},{\"question\":\"How does the trial compare treatments in Parts A and B?\",\"answer\":\"Part A (phase II) randomizes ~60 patients 1:1 to Dato-DXd 4 mg/kg or 6 mg/kg with platinum chemotherapy to determine optimal dosing. Part B (phase III) randomizes ~570 patients 1:1 to Dato-DXd at the recommended dose plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy.\"},{\"question\":\"What are the primary endpoints for each part of the study?\",\"answer\":\"Part A primary endpoint is objective response rate (ORR). Part B dual primary endpoints are progression-free survival (PFS) by blinded independent central review and overall survival.\"}]","TROPION-Urothelial03 - a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma | PDF",1790151519,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b24574149733ec1fe9d1641094db5909.webp",983,1280,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6722011c003875c64b817199518ca04e.webp",982,1278,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e642576ed7928b6052d3773c61989ff4.webp",981,1277,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b0cd87c8b4ac64d9b59ae42420710ed.webp",980,1276]